drugset / Trial / NCT06206564

Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

NCT06206564

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a phase II double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)

Timeline

Start
2024-01-12
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Artesunate Small molecule Topical